Literature DB >> 24078094

Association of CDKN1B gene polymorphisms with susceptibility to breast cancer: a meta-analysis.

Heping Xiang, He Li, Weiwei Ge, Weidong Wu, Ming Gao, Wei Wang, Lei Hong, Datong Jiang, Changle Zhang.   

Abstract

A number of case–control studies have been conducted to investigate the association of CDKN1B gene polymorphisms with breast cancer. However, these studies reported conflicting results. The aim of our study was to quantitatively summarize the association of CDKN1B gene polymorphisms with breast cancer. Systemic searches of the PubMed, Excerpta Medica Database, and Chinese Biomedical Literature Database databases were performed, with the last report up to Oct 2012. Odds ratios (ORs) with 95 % confidence intervals (CIs) were used to assess the strength of the association. Seven studies including 6,822 cases and 7,186 controls were involved in this meta-analysis, which was performed for two CDKN1B gene polymorphisms (rs2066827 and rs34330). Significant association was found for rs34330 polymorphism (T versus C: OR = 1.10, 95 % CI = 1.03–1.18, P = 0.003; CT + TT versus CC: OR = 1.38, 95 % CI = 0.98–1.93, P = 0.07; TT versus CC + CT: OR = 1.06, 95 % CI = 0.93–1.21, P = 0.38; TT versus CC: OR = 1.23, 95 % CI = 1.04–1.45, P = 0.02; CT versus CC: OR = 1.42, 95 % CI = 0.97–2.09, P = 0.07), but not for rs2066827 polymorphism (G versus T: OR = 0.99, 95 % CI = 0.91–1.08, P = 0.84; TG + GG versus TT: OR = 0.98, 95 % CI = 0.89–1.08, P = 0.69; GG versus TT + TG: OR = 1.04, 95 % CI = 0.83–1.30, P = 0.75; GG versus TT: OR = 1.03, 95 % CI = 0.82–1.30, P = 0.77; TG versus TT: OR = 0.97, 95 % CI = 0.88–1.08, P = 0.58). This meta-analysis suggests that breast cancer may be associated with CDKN1B gene rs34330 polymorphism, but not rs2066827 polymorphism.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 24078094     DOI: 10.1007/s11033-013-2751-8

Source DB:  PubMed          Journal:  Mol Biol Rep        ISSN: 0301-4851            Impact factor:   2.316


  31 in total

1.  Quantifying heterogeneity in a meta-analysis.

Authors:  Julian P T Higgins; Simon G Thompson
Journal:  Stat Med       Date:  2002-06-15       Impact factor: 2.373

2.  Meta-analysis in clinical trials.

Authors:  R DerSimonian; N Laird
Journal:  Control Clin Trials       Date:  1986-09

3.  CCND1 and CDKN1B polymorphisms and risk of breast cancer.

Authors:  Emel Canbay; Ilhan Yaylim Eraltan; Ali Cercel; Turgay Isbir; Ertugrul Gazioglu; Fatih Aydogan; Canan Cacina; Ali Cengiz; Mehmet Ferahman; Emel Zengin; Hilal Unal
Journal:  Anticancer Res       Date:  2010-07       Impact factor: 2.480

4.  Cancer statistics, 2010.

Authors:  Ahmedin Jemal; Rebecca Siegel; Jiaquan Xu; Elizabeth Ward
Journal:  CA Cancer J Clin       Date:  2010-07-07       Impact factor: 508.702

Review 5.  Regulation of the cdk inhibitor p27 and its deregulation in cancer.

Authors:  J Slingerland; M Pagano
Journal:  J Cell Physiol       Date:  2000-04       Impact factor: 6.384

6.  Allelic variant at -79 (C>T) in CDKN1B (p27Kip1) confers an increased risk of thyroid cancer and alters mRNA levels.

Authors:  Iñigo Landa; Cristina Montero-Conde; Donatella Malanga; Silvia De Gisi; Guillermo Pita; Luis-Javier Leandro-García; Lucía Inglada-Pérez; Rocío Letón; Carmela De Marco; Cristina Rodríguez-Antona; Giuseppe Viglietto; Mercedes Robledo
Journal:  Endocr Relat Cancer       Date:  2010-06-01       Impact factor: 5.678

7.  Mutational analysis of the human cyclin-dependent kinase inhibitor p27kip1 in primary breast carcinomas.

Authors:  A A Ferrando; M Balbín; A M Pendás; F Vizoso; G Velasco; C López-Otín
Journal:  Hum Genet       Date:  1996-01       Impact factor: 4.132

8.  Role of the ubiquitin-proteasome pathway in regulating abundance of the cyclin-dependent kinase inhibitor p27.

Authors:  M Pagano; S W Tam; A M Theodoras; P Beer-Romero; G Del Sal; V Chau; P R Yew; G F Draetta; M Rolfe
Journal:  Science       Date:  1995-08-04       Impact factor: 47.728

9.  Association of single-nucleotide polymorphisms in the cell cycle genes with breast cancer in the British population.

Authors:  Kristy E Driver; Honglin Song; Fabienne Lesueur; Shahana Ahmed; Nuno L Barbosa-Morais; Jonathan P Tyrer; Bruce A J Ponder; Douglas F Easton; Paul D P Pharoah; Alison M Dunning
Journal:  Carcinogenesis       Date:  2008-01-03       Impact factor: 4.944

Review 10.  Deregulation of p27 by oncogenic signaling and its prognostic significance in breast cancer.

Authors:  Angel Alkarain; Joyce Slingerland
Journal:  Breast Cancer Res       Date:  2003-10-21       Impact factor: 6.466

View more
  4 in total

1.  Loss of p27 expression is associated with MEN1 gene mutations in sporadic parathyroid adenomas.

Authors:  Simona Borsari; Elena Pardi; Natalia S Pellegata; Misu Lee; Federica Saponaro; Liborio Torregrossa; Fulvio Basolo; Elena Paltrinieri; Maria Chiara Zatelli; Gabriele Materazzi; Paolo Miccoli; Claudio Marcocci; Filomena Cetani
Journal:  Endocrine       Date:  2016-04-02       Impact factor: 3.633

2.  The functional variant rs34330 of CDKN1B is associated with risk of neuroblastoma.

Authors:  Mario Capasso; Lee D McDaniel; Flora Cimmino; Andrea Cirino; Daniela Formicola; Mike R Russell; Pichai Raman; Kristina A Cole; Sharon J Diskin
Journal:  J Cell Mol Med       Date:  2017-06-30       Impact factor: 5.310

3.  Genetic association between the cyclin-dependent kinase inhibitor gene p27/Kip1 polymorphism (rs34330) and cancer susceptibility: a meta-analysis.

Authors:  Xiao-Ke Cheng; Xue-Jun Wang; Xiao-Dong Li; Xue-Qun Ren
Journal:  Sci Rep       Date:  2017-03-20       Impact factor: 4.379

4.  MIAT inhibits proliferation of cervical cancer cells through regulating miR-150-5p.

Authors:  Yanbin Liu; Xingzhi Li; Hui Zhang; Yali Huang
Journal:  Cancer Cell Int       Date:  2020-06-15       Impact factor: 5.722

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.